application): In this Phase I grant application, the researchers propose to synthesize cationic and neutral oligonucleotides to enhance the binding affinity of synthetic oligonucleotides capable of sequence specific triple helix formation which can serve as reagents for directed gene knockout. Triplex-forming oligonucleotides (TFOs) have been shown to inhibit transcription and induce site-specific mutagenesis and recombination in mammalian cells. These reagents can be used as tools for genetic manipulation and have the potential to be developed into gene based therapeutics for cancer, viral infections, and inflammatory diseases. The applicants suggest that the efficiency and binding affinity of triplex targeting can be significantly improved by novel modifications of the oligonucleotides that have been developed in the researcher's laboratories.

Proposed Commercial Applications

NOT AVAILABLE

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43GM060087-01
Application #
6015332
Study Section
Special Emphasis Panel (ZRG1-SSS-Z (01))
Program Officer
Lees, Robert
Project Start
1999-08-01
Project End
2002-07-31
Budget Start
1999-08-01
Budget End
2002-07-31
Support Year
1
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Isis Pharmaceuticals, Inc.
Department
Type
DUNS #
City
Carlsbad
State
CA
Country
United States
Zip Code
92010